Rivaroxaban: clinical pharmacology;Rivaroxaban : données pharmaco-cliniques

Annales Francaises d'Anesthesie et de Reanimation

Volumn 27, Issue SUPPL. 3, 2008, Pages

  Mismetti, P ^a   Laporte, S ^a  

^a University Jean Monnet of Saint Etienne EA3065   (France)

Author keywords

Antithrombotic; Clinical pharmacology; Dose ranging study; Rivaroxaban; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; CYTOCHROME P450; ENOXAPARIN; RIVAROXABAN; UNCLASSIFIED DRUG; XARELTO;

ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; HIP FRACTURE; HUMAN; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; OPTIMAL DRUG DOSE; ORTHOPEDIC SURGERY; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLECULAR STRUCTURE; MORPHOLINES; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; PREANESTHETIC MEDICATION; THIOPHENES; VENOUS THROMBOSIS;

EID: 58949098587     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(08)75142-6     Document Type: Article

References (21)

1. Kubitza D., Becka M., Voith B., Zuehlsdorf M., and Wensing G. Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 (2005) 412-421
2. Kubitza D., Becka M., Wensing G., Voith B., and Zuehlsdorf M. Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939, an oral, direct factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61 (2005) 873-880
3. Mueck W., Becka M., and Kubitza D. Population model of the pharmacokinetic and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 45 (2007) 335-344
4. Kubitza D., Becka M., Mueck W., Wensing G., Voith B., and Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tlerability of rivaroxaban - an oral, direct factor Xa inhibitor. Blood 108 (2006) A905
5. Kubitza D., Becka M., Zuehlsdorf M., and Mueck W. Bodyweight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47 (2007) 218-226
6. Mueck W., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Fisher W.D., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokin 47 (2008) 203-216
7. Mueck W., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thrombembolism in patients undergoing total hip replacement. Thromb Haemost 100 (2008) 453-461
8. Mueck W., Agnelli G., and Büller H.R. Rivaroxaban has predictable pharmacokinetic and pharmacodynamics when given once or twice daily for the treatment of acute, proximal deep vein thrombosis. Blood 110 (2007) A1874
9. Gerotzafias G.T., Elalamy I., Depasse F., Perzborn E., and Samama m.m. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 5 (2007) 886-888
10. Walenga J.M., Prechel M., Jeske W.P., Hoppensteadt D., Maddinemi J., Iqbal O., et al. Rivaroxaban - an oral, direct factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 143 (2008) 92-99
11. Eriksson B.I., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Resaerch 120 (2007) 685-693
12. Turpie A.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., Kälebo P., et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3 (2005) 2479-2486
13. Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Oral, direct factor Xa inhibitor for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 (2006) 121-128
14. Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. A once daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114 (2006) 2374-2381
15. Fisher W.D., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Gent M., et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 97 (2007) 931-937
16. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., et al. Antithrombotic therapy in atrial fibrillation. ACCP evidence-based clinical pratice guidelines (8th edition). CHETS 133 (2008) 546S-592S
17. th edition). CHETS 133 (2008) 454S-545S
18. Agnelli G., Gallus A.S., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939), the ODIXa-DVT study. Circulation 116 (2007) 180-187
19. Büller H.R., Lensing A.W., Prins M.H., Agnelli G., Cohen A., Gallus A.S., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 112 (2008) 2242-2247
20. Fiessenger J.N., Huisman M.V., Davidson B.L., Bounameaux H., Francis C.W., Eriksoon H., et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293 (2005) 681-689
21. The Van Gogh investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007) 1094-1104